ITGAX and HIV-1 infection: Although CD11c+ CD8+ T cells may be a potential therapeutic target for combating acute infection and tumors in mouse models, the anti-HIV-1 activity of CD11c+ CD8+ T cells in patients with chronic HIV-1 infection remains unclear.